Opinion of the Transparency Council – valsartan + hydrochlorothiazide

At its meeting on 8 May 2023, the Transparency Council adopted Opinion No. 93/2023 on the inclusion in the reimbursement procedure of medicines containing the active substances valsartan + hydrochlorothiazide for selected off-label indications.

Publication on the list of opinions on active substances for off-label indications